share_log

Arch Therapeutics Accepted to Present AC5® Advanced Wound System During Innovation Spotlight at 2022 Symposium on Advanced Wound Care (SAWC)

Arch Therapeutics Accepted to Present AC5® Advanced Wound System During Innovation Spotlight at 2022 Symposium on Advanced Wound Care (SAWC)

ARCH治療公司在2022年高級傷口護理研討會上接受邀請在創新聚光燈下推出AC5®高級傷口系統
GlobeNewswire ·  2022/09/20 06:55

Prestigious Honor Supports Increasing Interest in Broad Clinical Benefits of Synthetic Products in Wound Healing

聲望卓著的榮譽支持人們對合成產品在傷口癒合方面的廣泛臨牀好處越來越感興趣

FRAMINGHAM, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that AC5® Advanced Wound System ("AC5") was selected for the "Innovation Spotlight: Shining a Light on Bold Ideas in Wound Care" session at the 2022 Symposium on Advanced Wound Care ("SAWC"). The prestigious honor represents the Company's second consecutive Innovation Spotlight acceptance. The session is being held at Caesars Palace, Las Vegas, Nevada on October 16, 2022, between 11:20 AM to 12:20 PM PT during the SAWC Annual Conference.

馬薩諸塞州弗雷明翰,9月2022年10月20日(環球通訊社)--Arch治療公司(場外交易代碼:ARTH)(“拱形“或”公司),一家新型自組裝傷口護理和生物外科產品的營銷商和開發商,今天宣佈AC5®在2022年高級創傷護理研討會(“SAWC”)上,先進傷口護理系統(“AC5”)被選為“創新聚光燈:照亮傷口護理中的大膽想法”環節。這一享有盛譽的榮譽代表着該公司連續第二次獲得創新聚焦獎。會議將於2022年10月16日在內華達州拉斯維加斯凱撒宮舉行,時間為太平洋標準時間上午11:20至下午12:20。

AC5 is a novel self-assembling wound care product and is the first to provide clinicians with multi-modal support and utility across all phases of wound healing. AC5 was cleared by the Food and Drug Administration ("FDA") for the management of partial and full-thickness wounds, such as pressure sores, leg ulcers, diabetic ulcers, and surgical wounds.

AC5是一種新型的自組裝傷口護理產品,是第一個為臨牀醫生提供跨傷口癒合所有階段的多模式支持和實用程序的產品。AC5已被美國食品和藥物管理局(FDA)批准用於治療部分和全層傷口,如壓瘡、腿部潰瘍、糖尿病潰瘍和手術傷口。

Key opinion leader, Dr. Brock Liden, who recently agreed to serve as the Primary Investigator for the Company's multi-site clinical study for AC5, will be leading the Innovation Spotlight presentation. The discussion is expected to highlight the broad clinical benefits of AC5 in chronic and non-healing wounds. Dr. Liden stated, "AC5 contains a unique synthetic self-assembling peptide matrix that binds to the host tissue to build both a barrier and scaffold in the wound bed. In my experience, I believe these processes reduce bacterial contamination and support cell migration and organization, which together help accelerate wound healing and improve outcomes."

主要意見領袖布羅克·利登博士最近同意擔任該公司AC5多點臨牀研究的主要調查員,他將領導創新聚焦演講。預計討論將突出AC5在慢性和不可癒合傷口中的廣泛臨牀益處。Liden博士説:“AC5含有一種獨特的合成自組裝肽基質,它與宿主組織結合在一起,在傷口牀上建立屏障和支架。根據我的經驗,我相信這些過程減少了細菌污染,支持了細胞遷移和組織,共同幫助加速傷口癒合和改善結果。”

"The Innovation Spotlight acceptance confirms increasing interest in the unique benefits of AC5, and we are honored to have key opinion leaders like Dr. Liden discussing its clinical use with peers and contributing to our growing body of data on its effectiveness. These peer-to-peer educational events support both our near and long-term revenue growth opportunities," stated Dan Yrigoyen, Vice President of Sales of Arch Therapeutics.  

Arch Treeutics銷售部副總裁丹·伊裏戈延表示:“創新聚焦獎的獲獎證明,人們對AC5的獨特益處越來越感興趣,我們很榮幸能有像Liden博士這樣的重要意見領袖與同行討論它的臨牀應用,併為我們越來越多的關於其有效性的數據做出貢獻。這些點對點教育活動為我們提供了近期和長期的收入增長機會。”

The Symposium on Advanced Wound Care (SAWC) is the largest gathering of multidisciplinary wound care clinicians in the United States. Continuing education credits are offered for physicians, nurses, pharmacists, podiatrists, physical therapists, and dieticians. More information on the event is available at
About Arch Therapeutics, Inc.

高級傷口護理研討會(SAWC)是美國多學科傷口護理臨牀醫生最大的聚會。為醫生、護士、藥劑師、足科醫生、物理治療師和營養師提供繼續教育學分。有關此次活動的更多信息,請訪問
Arch治療公司簡介

Arch Therapeutics, Inc. is a biotechnology company with a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma, and interventional care. Arch is developing wound care and biosurgical products based on an innovative self-assembling peptide technology platform with the goal of improving healing outcomes for patients. Arch has received regulatory clearance to market AC5® Advanced Wound System in the United States and AC5® Topical Hemostat in Europe. Arch's development stage product pipeline includes AC5-G™ for endoscopic resection of gastrointestinal tumors, AC5-V® for hemostasis during vascular surgery and AC5 Surgical Hemostat for general surgical hemostasis, among others.1,2

ARCH治療公司是一家生物技術公司,擁有一種新的方法來止血(止血)、控制泄漏(密封劑)並在手術、創傷和介入治療中處理傷口。ARCH正在開發基於創新的自組裝肽技術平臺的傷口護理和生物外科產品,目標是改善患者的癒合結果。ARCH已獲得上市AC5的監管許可®美國和AC5的先進創傷系統®歐洲的局部止血器。ARCH的開發階段產品線包括用於胃腸道腫瘤內窺鏡切除的AC5-G™,AC5-V®用於血管手術止血,AC5外科止血器用於普通外科止血等。1,2

Notice Regarding Forward-Looking Statements

關於前瞻性陳述的通知

This news release contains "forward-looking statements" as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our ability to recruit additional field sales representatives and their effectiveness, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to obtain required regulatory approvals, our ability to produce commercial quantities of our products within projected timeframes, our ability to obtain the inclusion of our AC5® Advanced Wound System on targeted federal supply schedules, our ability to develop and commercialize products based on our technology platform, and market conditions, and our ability to establish additional commercialization partnerships and build a critical mass of field sales representatives. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.

本新聞稿包含“前瞻性陳述”,這一術語在修訂後的1933年證券法第27A節和修訂後的1934年證券交易法第21E節中有定義。本新聞稿中非純粹歷史性的陳述為前瞻性陳述,包括有關對未來的信念、計劃、期望或意圖的任何陳述。此類前瞻性陳述包括對新技術和方法的提及、我們招聘更多現場銷售代表的能力及其有效性、我們的業務和產品發展計劃和預測,或市場信息。由於許多因素,實際結果可能與任何前瞻性陳述中預測的結果不同。這些因素包括與開發新產品或技術和作為發展階段公司運營有關的內在不確定性,我們留住管理團隊重要成員和吸引其他合格人員的能力,我們籌集額外資金繼續執行我們的業務和產品開發計劃的能力,我們獲得必要的監管批准的能力,我們在預計的時間框架內生產商業批量產品的能力,我們獲得AC5的能力®我們在目標聯邦供應時間表上的先進傷口系統,我們基於我們的技術平臺和市場條件開發和商業化產品的能力,以及我們建立更多商業化合作夥伴關係和建立關鍵數量的現場銷售代表的能力。這些前瞻性陳述是截至本新聞稿發佈之日作出的,我們沒有義務更新前瞻性陳述,也沒有義務更新實際結果可能與前瞻性陳述中預測的結果不同的原因。儘管我們相信本新聞稿中包含的任何信念、計劃、預期和意圖都是合理的,但不能保證任何此類信念、計劃、預期或意圖將被證明是準確的。投資者應參考本文提供的所有信息,也應參考我們提交給美國證券交易委員會的報告和其他文件中概述的風險因素披露,這些文件可在www.sec.gov上獲得。

Contact:
ARTH Investor Relations
Toll Free: +1.855.340.ARTH (2784) (US and Canada)
Email: investors@archtherapeutics.com
Website:

聯繫方式:
Arth投資者關係
免費電話:+1.855.340.ARTH(2784)(美國和加拿大)
電子郵件:Investors@ArchTreateutics.com
網站:

or

Michael Abrams
Chief Financial Officer
Arch Therapeutics, Inc.
Phone: 617.431.2333
Email: mabrams@archtherapeutics.com

邁克爾·艾布拉姆斯
首席財務官
ARCH治療公司
電話:617.431.2333
電子郵件:mabram@archTreateutics.com


1 AC5-G, AC5-V, and AC5 Surgical Hemostat are currently investigational devices limited by law to investigational use.
2 AC5, AC5-G, AC5-V and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.

1AC5-G、AC5-V和AC5外科止血器目前是受法律限制的研究設備,只能用於研究用途。
2AC5、AC5-G、AC5-V和相關標識是Arch治療公司和/或其子公司的商標和/或註冊商標。


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論